Exit
In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing score of at least 75% on this post-survey, as well as complete the evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your area of specialty? 

Question Title

* 3. How many years have you been in practice?

Question Title

* 4. Please select the option that best describes your practice setting:

Question Title

* 5. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 6. After participating in this activity, how confident are you in the management of patients with ALL in your practice?

Question Title

* 7. Which of the following best describes how asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) asparaginase erwinia chrysanthemi (ERW) are similar?

Question Title

* 8. SP is a 10-year-old male who developed a grade 3 hypersensitivity reaction after his 3rd dose of pegaspargase on COG protocol AALL0232 for high-risk ALL. The pharmacy is unable to obtain ERW due to drug shortage.

Which of the following is most appropriate for SP?

Question Title

* 9. Which of the following was observed in serum asparaginase activity in the phase 2/3 clinical trial that led to FDA-approval of asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) in cohort 1a (25 mg/m2 IM on Monday, Wednesday, Friday)?

Evaluation Form
In order to receive a CME/CE certificate for your participation in this activity, please complete this form in its entirety.

Question Title

* 10. How committed are you to making changes in your practice based on your participation in this activity?

Question Title

* 11. Which of the following best describes the impact of this activity on your performance?

Question Title

* 12. Which new strategies/skills/information will you apply to your area of practice?

Question Title

* 13. What barriers do you see to making changes in your practice?

Question Title

* 14. After participating in today’s activity, I am now better able to:

  Strongly agree Agree Neutral Disagree Strongly disagree
Compare asparaginase erwinia chrysanthemi (recombinant)-rywn (ERW-rywn) with asparaginase erwinia chrysanthemi (ERW) based on efficacy, toxicity, manufacturing, dosing and administration
Describe the dosing, efficacy and safety of erwinia chrysanthemi (recombinant)-rywn (ERW-rywn)

Question Title

* 15. The following faculty presenter effectively presented the material:

  Strongly agree Agree Neutral Disagree Strongly disagree
Ryan D. Cassaday, MD
Luke Maese, DO

Question Title

* 16. The content presented:

  Strongly agree Agree Neutral Disagree Strongly disagree
Enhanced my current knowledge base
Addressed my most pressing questions
Promoted improvements or quality in health care
Was scientifically rigorous and evidence based
Avoided commercial bias or influence

Question Title

* 17. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 18. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?

Question Title

* 19. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities for this or related ALL:

Question Title

* 20. Please let us know who you are so we can connect your responses to your pre-test & application to claim CME credit.

Question Title

* 21. I certify that I have participated in the continuing education activity entitled, “In the Know: Key Abstracts from the American Society of Hematology 2021 Annual Meeting in Acute Lymphoblastic Leukemia" and claim 0.5 AMA PRA Category 1 CreditTM.

( Privacy & Cookie Notice

T